Astute Medical receives $30M from funding partner

Astute Medical will receive $30 million from funding partner CRG. The funds will go towards commercialization of the diagnostic NephroCheck Test System for acute kidney injury, and an additional $10 million will become available to Astute when it achieves certain preset revenue milestones. The FDA recently cleared the system and give its stamp of approval for Astute to start selling the product to the public. Release

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.